Details for Patent: 10,286,029
✉ Email this page to a colleague
Which drugs does patent 10,286,029 protect, and when does it expire?
Patent 10,286,029 protects MAVYRET and is included in two NDAs.
Protection for MAVYRET has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has one hundred and seven patent family members in twenty-six countries.
Summary for Patent: 10,286,029
| Title: | Method for treating HCV |
| Abstract: | The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof. |
| Inventor(s): | Awni; Walid M. (Green Oaks, IL), Bernstein; Barry M. (Mequon, WI), Campbell; Andrew L. (Lake Forest, IL), Dutta; Sandeep (Lincolnshire, IL), Lin; Chih-Wei (Vernon Hills, IL), Liu; Wei (Mundelein, IL), Menon; Rajeev M. (Buffalo Grove, IL), Podsadecki; Thomas J. (Chicago, IL), Wang; Tianli (Lake Bluff, IL), Mensing; Sven (Mannheim, DE) |
| Assignee: | AbbVie Inc. (North Chicago, IL) |
| Application Number: | 14/676,370 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 10,286,029
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | MAVYRET | glecaprevir; pibrentasvir | PELLETS;ORAL | 215110-001 | Jun 10, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Abbvie | MAVYRET | glecaprevir; pibrentasvir | TABLET;ORAL | 209394-001 | Aug 3, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,286,029
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2014239563 | ⤷ Try a Trial | |||
| Australia | 2015240754 | ⤷ Try a Trial | |||
| Australia | 2016202823 | ⤷ Try a Trial | |||
| Australia | 2016291154 | ⤷ Try a Trial | |||
| Australia | 2017248487 | ⤷ Try a Trial | |||
| Australia | 2018201011 | ⤷ Try a Trial | |||
| Australia | 2018311684 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
